Inclusion Criteria:

- Pathologic confirmation of NSCLC

- Patients must have previously untreated stage IB-IIIA NSCLC (T1-3N0-2M0)

- Patients must have lung cancer with a documented EGFR activating mutation (exon 19
deletion, L858R, L861Q)

- Patients must be candidates for resection with curative intent

- Measurable disease, defined as at least one lesion that can be accurately measured in
at least one dimension (longest diameter to be recorded on CT)

- Age greater or equal to 18 years

- Karnofsky performance status greater or equal to 70%

- Normal marrow function: leukocytes greater than or equal to 3,000/μl, absolute
neutrophil count greater than or equal to 1,500/μl, platelets greater than or equal
to 100,000/μl, hemoglobin greater than or equal to 9 gm/dl

- Adequate renal function, with creatinine less than or equal to 1.3 mg/dl or
calculated creatinine clearance greater to or equal to 60ml/min by Cockroft and Gault
equation using parameters of age, weight (kg), and baseline serum creatinine (mg/dl)

- Adequate hepatic function: Total bilirubin within normal limits, AST < 1.5 X UNL,
alkaline phosphatase < 1.5 X UNL

- Women of childbearing age must have a negative urine or blood pregnancy test

- Men and women of childbearing potential must be willing to consent to using effective
contraception while on treatment and for at least 3 months thereafter

- Patients must have ability to understand and the willingness to sign a written
informed consent document

Exclusion Criteria:

- Prior chemotherapy or radiation therapy, with the exception of chemotherapy for
nononcologic conditions (ie, methotrexate for the treatment of rheumatoid arthritis)

- Prior treatment with gefitinib, erlotinib, or other drugs that target EGFR

- Patients must not be receiving any other investigational agents

- Any evidence of interstitial lung disease (patients with chronic stable radiographic
changes who are asymptomatic need not be excluded)

- Patients who report a hearing deficit at baseline, even if it does not require a
hearing aid or intervention, or interfere with activities of daily life (CTCAE grade
2 or higher)

- Peripheral neuropathy > grade 1

- Known HIV-positive patients receiving combination anti-retroviral therapy are
excluded from the study because of possible pharmacokinetic interactions with the
study drugs.

- Other serious illness or medical condition including unstable cardiac disease
requiring treatment, history of significant neurologic or psychiatric disorders
(including psychotic disorders, dementia, or seizures), or active uncontrolled
infection

- Women who are pregnant or breast-feeding

- Psychiatric illness or social situation that would limit compliance with study
requirements